In short
Clinical trials are investigating Vx-522 in people with cystic fibrosis. This article explains what the study looked at, including safety, tolerability, and immune response, and who could take part. The trial also included a group receiving Vx-522 with ivacaftor.
Key points
- Clinical trials are studying Vx-522 in people with cystic fibrosis. The available study was a Phase 1/2 interventional trial with 36 participants and is now completed. It tested single ascending doses, multiple ascending doses, and a group that received Vx-522 with ivacaftor. The main goal was to assess safety and tolerability. Researchers also measured laboratory tests, heart checks, breathing tests, vital signs, pulse oximetry, and immune response through the Week 8 visit.
Trial overview
The available clinical trial studied Vx-522 in people with cystic fibrosis. It was an interventional study, which means researchers gave a study treatment and then measured the effects. The trial was Phase 1/2 and is listed as Completed.
Study design and treatment groups
The study included a single ascending dose part, often called SAD, to evaluate safety and tolerability after one dose. It also included a multiple ascending dose part, called MAD, to evaluate safety and tolerability after repeated doses. One treatment arm studied Vx-522 together with ivacaftor, which is named in the trial data as a co-administered treatment.
The intervention list shows Vx-522 as a nebuliser dispersion given by inhalation, and ivacaftor as an oral tablet in one arm. Nebuliser dispersion means the medicine is turned into a mist for breathing in.
Who participated
The trial enrolled 36 subjects with cystic fibrosis. The source data do not provide more detailed inclusion or exclusion rules, so the main known target population is people with cystic fibrosis.
What was measured in the study
The main outcome was safety and tolerability through the Week 8 visit. Safety was checked using adverse events, clinical laboratory values, standard 12-lead ECGs, vital signs, pulse oximetry, spirometry, and immune response to Vx-522 components and CFTR protein.
Adverse events are unwanted medical problems that happen during a study, whether or not they are caused by the treatment. Pulse oximetry is a simple test that measures oxygen level in the blood, and spirometry is a breathing test that checks lung function.
What this article focuses on
This article focuses on the clinical research questions behind Vx-522, not on how the treatment works in the body. The key questions in the trial were whether Vx-522 could be given safely, how well it was tolerated, and how the body responded over time in people with cystic fibrosis.